Enliven Therapeutics, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating items
Research & Development 38.44M18.94M
Selling, General & Administrative 13.00M15.33M
Other Operating Expenses 35.00M
Operating Expenses 51.44M34.27M
Operating Income -51.44M0.73M
EBIT -51.44M0.73M
Non-operating items
Interest & Investment Income 0.23M0.94M
Other Non Operating Income -0.17M-0.10M
Non Operating Income -0.17M0.85M
Net income details
EBT -51.38M1.58M
Tax Provisions 0.09M
Profit After Tax -51.38M1.49M
Income from Continuing Operations -51.38M1.49M
Consolidated Net Income -51.38M1.49M
Income towards Parent Company -51.38M1.49M
Net Income towards Common Stockholders -51.38M1.49M
Additional items
EPS (Basic) -0.00M0.00M
EPS (Weighted Average and Diluted) -0.00M0.00M
Shares Outstanding (Weighted Average) 4.08M4.35M6.57M6.57M41.21M48.86M
EBITDA -51.40M1.50M
Tax Rate 5.58%